Nicolas Mach

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites

Chris S. Lantz, Jürg Boesiger, Chang Ho Song et al. · Nature · 1998 · 572 citations · Full text

Veterinary Medicine, Cell Biology, Immunology +12

Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.

Nicolas Mach, Silke Gillessen, S. Brian Wilson et al. · PubMed · 2000 · 413 citations

Life Sciences, Immunology, Oncology +17

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et al. · Clinical Cancer Research · 2021 · 348 citations · Full text

Pharmacy, Oncology, Pharmacology +17

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet et al. · Journal of Clinical Oncology · 2021 · 341 citations

Medicine, Oncology, Pharmacotherapy +13